Literature DB >> 24899058

APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.

Xiqian Lan1, Aakash Jhaveri1, Kang Cheng1, Hongxiu Wen1, Moin A Saleem2, Peter W Mathieson2, Joanna Mikulak3, Sharon Aviram4, Ashwani Malhotra1, Karl Skorecki4, Pravin C Singhal5.   

Abstract

Development of higher rates of nondiabetic glomerulosclerosis (GS) in African Americans has been attributed to two coding sequence variants (G1 and G2) in the APOL1 gene. To date, the cellular function and the role of APOL1 variants (Vs) in GS are still unknown. In this study, we examined the effects of overexpressing wild-type (G0) and kidney disease risk variants (G1 and G2) of APOL1 in human podocytes using a lentivirus expression system. Interestingly, G0 inflicted podocyte injury only at a higher concentration; however, G1 and G2 promoted moderate podocyte injury at lower and higher concentrations. APOL1Vs expressing podocytes displayed diffuse distribution of both Lucifer yellow dye and cathepsin L as manifestations of enhanced lysosomal membrane permeability (LMP). Chloroquine attenuated the APOL1Vs-induced increase in podocyte injury, consistent with targeting lysosomes. The chloride channel blocker DIDS prevented APOL1Vs- induced injury, indicating a role for chloride influx in osmotic swelling of lysosomes. Direct exposure of noninfected podocytes with conditioned media from G1- and G2-expressing podocytes also induced injury, suggesting a contributory role of the secreted component of G1 and G2 as well. Adverse host factors (AHFs) such as hydrogen peroxide, hypoxia, TNF-α, and puromycin aminonucleoside augmented APOL1- and APOL1Vs-induced podocyte injury, while the effect of human immunodeficiency virus (HIV) on podocyte injury was overwhelming under conditions of APOLVs expression. We conclude that G0 and G1 and G2 APOL1 variants have the potential to induce podocyte injury in a manner which is further augmented by AHFs, with HIV infection being especially prominent.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  APOL1 risk variants; kidney disease; lysosomal membrane permeability; necrosis; podocyte

Mesh:

Substances:

Year:  2014        PMID: 24899058      PMCID: PMC4121568          DOI: 10.1152/ajprenal.00647.2013

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  48 in total

1.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease.

Authors:  Derek M Fine; Walter G Wasser; Michelle M Estrella; Mohamed G Atta; Michael Kuperman; Revital Shemer; Arun Rajasekaran; Shay Tzur; Lorraine C Racusen; Karl Skorecki
Journal:  J Am Soc Nephrol       Date:  2011-12-01       Impact factor: 10.121

3.  Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy.

Authors:  O Gasser; C Brander; M Wolbers; N V Brown; A Rauch; H F Günthard; M Battegay; C Hess
Journal:  HIV Med       Date:  2012-08-30       Impact factor: 3.180

4.  Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin.

Authors:  Jochen Reiser; Jun Oh; Isao Shirato; Katsuhiko Asanuma; Andreas Hug; Thomas M Mundel; Karen Honey; Kazumi Ishidoh; Eiki Kominami; Jordan A Kreidberg; Yasuhiko Tomino; Peter Mundel
Journal:  J Biol Chem       Date:  2004-06-14       Impact factor: 5.157

5.  A cytosolic source of calcium unveiled by hydrogen peroxide with relevance for epithelial cell death.

Authors:  J Castro; C X Bittner; A Humeres; V P Montecinos; J C Vera; L F Barros
Journal:  Cell Death Differ       Date:  2004-04       Impact factor: 15.828

6.  APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair.

Authors:  Tomek Kofman; Vincent Audard; Céline Narjoz; Olivier Gribouval; Marie Matignon; Claire Leibler; Dominique Desvaux; Philippe Lang; Philippe Grimbert
Journal:  Am J Kidney Dis       Date:  2014-02-08       Impact factor: 8.860

7.  Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.

Authors:  Barry I Freedman; Carl D Langefeld; Jolyn Turner; Marina Núñez; Kevin P High; Mitzie Spainhour; Pamela J Hicks; Donald W Bowden; Amber M Reeves-Daniel; Mariana Murea; Michael V Rocco; Jasmin Divers
Journal:  Kidney Int       Date:  2012-06-13       Impact factor: 10.612

8.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

9.  APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis.

Authors:  Duncan B Johnstone; Vijay Shegokar; Deepak Nihalani; Yogendra Singh Rathore; Leena Mallik; Vasant Zare; H Omer Ikizler; Rajaram Powar; Lawrence B Holzman
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  Morphine induces albuminuria by compromising podocyte integrity.

Authors:  Xiqian Lan; Partab Rai; Nirupama Chandel; Kang Cheng; Rivka Lederman; Moin A Saleem; Peter W Mathieson; Mohammad Husain; John T Crosson; Kalpna Gupta; Ashwani Malhotra; Pravin C Singhal
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more
  97 in total

1.  How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.

Authors:  Chien-An A Hu; Patricio E Ray
Journal:  Nephrol Dial Transplant       Date:  2015-10-03       Impact factor: 5.992

Review 2.  ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus.

Authors:  Ashira D Blazer; Robert M Clancy
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

3.  Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Authors:  Herbert Lannon; Shrijal S Shah; Leny Dias; Daniel Blackler; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2019-08-01       Impact factor: 10.612

4.  Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization.

Authors:  Hanghang Wang; Patrick H Pun; Lydia Kwee; Damian Craig; Carol Haynes; Megan Chryst-Ladd; Laura P Svetkey; Uptal D Patel; Elizabeth R Hauser; Martin R Pollak; William E Kraus; Svati H Shah
Journal:  Cardiorenal Med       Date:  2016-12-29       Impact factor: 2.041

Review 5.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

6.  Hedgehog pathway plays a vital role in HIV-induced epithelial-mesenchymal transition of podocyte.

Authors:  Xiqian Lan; Hongxiu Wen; Kang Cheng; Andrei Plagov; Seyedeh Shadafarin Marashi Shoshtari; Ashwani Malhotra; Pravin C Singhal
Journal:  Exp Cell Res       Date:  2017-01-31       Impact factor: 3.905

7.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

8.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

9.  Apolipoprotein L1-associated nephropathy and the future of renal diagnostics.

Authors:  Christopher P Larsen; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2015-01-08       Impact factor: 10.121

10.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.